Quantity of eligible individuals: CDEC mentioned the uncertainty in the number of patients with reasonably intense to intense hemophilia B in Canada suitable for etranacogene dezaparvovec. Medical professionals consulted by CADTH indicated that some people that are categorized as possessing mild or average disorder could have a serious bleeding phenotype, https://hemgenix15677.bloggip.com/35866665/not-known-details-about-hemgenix